DeliNova Therapeutics raises $8.3 million to drive in vivo CAR-T pipeline

Chinese biotech DeliNova Therapeutics has completed its seed and angel funding rounds, raising 60 million yuan ($8.3 million) to advance its in vivo CAR-T technology platform and push its first candidate toward clinical testing. The Nantong-based company focuses on developing innovative in-body CAR-T and gene therapy approaches.

The round drew investors including Shanghai Jiao Tong University Hanyuan VC, Legend Capital, CAS Star, Vision Investment, and Hongfeng Investment.

DeliNova said the funds will accelerate optimization of its multi-dimensional lentiviral vector platform, expand its scientific team, and support clinical translation for hematologic malignancies and autoimmune diseases. An investigator-initiated trial is expected to begin soon.